- FDA Approves Expanded Injectable Treatment Formula for Smallpox-Monkeypox
- UK and Netherlands follow Belgium to implement “monkeypox quarantine”
- European EMA removes about 100 generic drugs
- EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- First injection of cancer-killing oncolytic virus into human patient
- First monkeypox quarantine order: Belgium requires to self-isolate for 21 days
WHO releasesd new guidelines for cervical cancer screening and listed HPV-DNA test first
WHO releasesd new guidelines for cervical cancer screening and listed HPV-DNA test first. Cervical cancer is a preventable and curable disease, but a large number of women still die of cervical cancer every year around the world.
The World Health Organization and the United Nations Special Programme for Human Reproduction jointly issued a new guide on the 6th to help countries better carry out cervical cancer screening and treatment, which recommends HPV-DNA (human papillomavirus-deoxyribonucleic acid) testing As the preferred screening method for cervical cancer screening.
According to WHO data, there will be more than 500,000 new cases of cervical cancer worldwide in 2020, and about 340,000 women will die of cervical cancer. Human papillomavirus is considered to be the culprit for cervical cancer and other cancers. For example, cervical cancer and precancerous lesions caused by human papillomavirus types 16 and 18, which are high-risk types, account for about 70% of the total. Therefore, a fast and accurate screening method for human papillomavirus is very important, allowing women with cervical disease to be treated and avoid death.
Compared with the previous guidelines, the new guidelines make some important changes in cervical cancer screening. At present, the commonly used screening method for cervical precancerous lesions is mainly “smear examination”, and the new guidelines recommend HPV-DNA testing as the preferred screening method.
The new guidelines say that HPV-DNA testing can detect high-risk strains of human papillomavirus. Unlike the smear method that relies on naked eye observation, HPV-DNA testing is an objective diagnosis. In addition, the HPV-DNA detection operation is simpler and the cost is not high.
The World Health Organization urges women all over the world to follow the recommendations of local medical institutions for regular cervical cancer screening. However, some women with impaired immune function, such as those infected with HIV, are more likely to suffer from cervical disease and will develop into precancerous lesions and cervical cancer more quickly. For this reason, the new guidelines specifically provide recommendations for women living with HIV, such as the use of HPV-DNA testing for preliminary screening, and if the result is positive, a typing test will be performed to assess the risk of cervical cancer and the need for treatment.
The new guidelines emphasize that ordinary women can be screened for cervical cancer at the age of 30, while women living with HIV must be screened before the age of 25.
(source:internet, reference only)